Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • NeuroPace's Share-based Compensation rose 142.8% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 1045.24%. This contributed to the annual value of $10.3 million for FY2024, which is 757.48% up from last year.
  • Per NeuroPace's latest filing, its Share-based Compensation stood at $2.6 million for Q3 2025, which was up 142.8% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, NeuroPace's Share-based Compensation registered a high of $3.2 million during Q2 2025, and its lowest value of $202000.0 during Q1 2021.
  • For the 5-year period, NeuroPace's Share-based Compensation averaged around $2.2 million, with its median value being $2.4 million (2023).
  • Per our database at Business Quant, NeuroPace's Share-based Compensation plummeted by 3289.04% in 2021 and then skyrocketed by 63663.37% in 2022.
  • NeuroPace's Share-based Compensation (Quarter) stood at $1.9 million in 2021, then grew by 10.66% to $2.1 million in 2022, then rose by 13.54% to $2.4 million in 2023, then grew by 10.44% to $2.6 million in 2024, then rose by 0.96% to $2.6 million in 2025.
  • Its Share-based Compensation was $2.6 million in Q3 2025, compared to $3.2 million in Q2 2025 and $2.6 million in Q1 2025.